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PURPOSE. The purpose of this study was to explore the relationship between visual acuity and
utility (health-related quality of life) in diabetic macular edema (DME) using intravitreal
aflibercept data.
METHODS. The relationship between visual acuity in the best-seeing eye (BSE) and worse-
seeing eye (WSE) and utility was explored using ordinary least squares (OLS) and random-
effects models adjusted for different covariates (age, age2, sex, body mass index, smoking
status, glycated hemoglobin, diabetes severity, comorbidities, and geographic region). Utility
was measured using the EuroQoL-five dimensions questionnaire (EQ-5D) and Visual
Functioning Questionnaire-Utility Index (VFQ-UI). For each model, coefficients (R2) were
reported, and WSE/BSE was expressed as the ratio of coefficients (OLS models). Models were
independent of treatment effects, and outcomes from all time points (up to week 100) were
included where available.
RESULTS. Data from 1320 patients with DME were analyzed. In all models, the association
between visual acuity (BSE > WSE) was stronger with VFQ-UI– than EQ-5D–derived utilities.
The estimated relationship between VFQ-UI and visual acuity in the BSE and WSE was robust,
even with an increasing number of covariates. WSE/BSE coefficient ratios were similar across
VFQ-UI OLS models (32%) compared with EQ-5D models (41%–48%). Actual (unadjusted)
versus predicted data plots also showed a better fit with VFQ-UI– than EQ-5D–derived
utilities.
CONCLUSIONS. These analyses show that VFQ-UI was more sensitive than EQ-5D–derived
utilities for measuring the impact of visual acuity in the BSE and WSE. Visual acuity in the BSE
was a major contributor to utility, but WSE is also important though to a lesser degree as
shown by the coefficient ratios. These new data will be useful for health technology
assessments in DME, where utilities data are lacking.
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In clinical decision-making, interventions are primarilyassessed based on efficacy and safety. However, it is also
important to monitor the impact that treatments have on utility
(i.e., health-related quality of life) using validated instru-
ments.1,2 This is particularly relevant in chronic eye conditions,
such as diabetic macular edema (DME), for which treatments
are invasive and long term, but usually sight saving. Utility is a
measure of health preference anchored around a value of 1 for
perfect health and 0 for dead that is used in calculations of
quality-adjusted life years (QALY). Unfortunately, patient utility
assessments are often inferred from studies based on vision
outcomes in one treated eye, which is not a complete
assessment of visual functioning.3,4 In addition, the EuroQoL-
five dimensions questionnaire (EQ-5D), a commonly used
generic instrument for measuring utility in retinal studies, lacks
a vision-related domain; this insensitivity has been observed
across all retinal conditions.2,5–8
Most health technology assessments of treatments, including
those for use in retinal conditions, are based on utility data
generated in studies for the product under assessment. For such
evaluations, the National Institute for Health and Care
Excellence (NICE) states that the EQ-5D is the preferred
measure of health-related quality of life in adults.9 They also
acknowledge that the EQ-5D may not be appropriate in some
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cases, but that additional evidence must be provided to
support alternatives, including validation of data.9 Most
recently, a NICE appraisal committee recognized that EQ-5D
values may underestimate the effect of retinal conditions on
health-related quality of life, including the impact of improve-
ments in best-corrected visual acuity (BCVA).10 There are
several alternative methods that can be used, such as
condition-specific, preference-based methods; although these
are acceptable by the NICE methods guidance, further research
on such approaches is recommended.11,12 The latest Interna-
tional Society for Pharmacoeconomics and Outcomes Research
(ISPOR) guidelines also acknowledge the use of health-related
quality of life instruments that can be mapped to health
utility.13 The ISPOR guidelines emphasize the importance of
capturing actual patient experience using patient-reported
outcomes and ensuring that they are valued and converted into
utility. Outside of the United States, valuation should be based
on a representative sample from the general population using a
choice-based method.13 The algorithm of Rentz et al. is one
such method that is valued by a general population sample.14 It
is used to convert data obtained via the National Eye Institute
Visual Functioning Questionnaire-25 (NEI-VFQ-25), an ophthal-
mology-specific measure that has been validated in patients
with DME and other retinal conditions,15–17 into a condition-
specific, preference-based measure that defines visual function
health states (the Visual Functioning Questionnaire-Utility
Index [VFQ-UI]). It is therefore ideal for exploring the issues
described in more detail.
In addition, economic models in a bilateral disease, such as
DME, should ideally track outcomes in each eye. NICE has
criticized prior economic model submissions of anti-VEGF
agents in which this has not been done appropriately.18
Although the best-seeing eye (BSE) is regarded as the most
important parameter for determining daily visual functioning,
the independent contribution of the worse-seeing eye (WSE) is
based on expert opinion and estimates rather than new
research.3,19–21 It would therefore be important to determine
the contribution of the WSE in more detail using actual data
rather than estimates.
Based on these considerations, including the need for
further research to assess the appropriateness of the EQ-5D
and the validation of condition-specific, preference-based
measures, we used actual patient-generated EQ-5D and NEI-
VFQ-25 data from four intravitreal aflibercept injection (IAI)
studies22 (NCT01512966 and NCT01783886) to develop new
utility data in DME. Specifically, the aims of this analysis were
to apply the algorithm of Rentz et al. using actual NEI-VFQ-25
data from the IAI studies; identify the most suitable statistical
model to explain variation in patient utility in DME, enabling
comparison of EQ-5D and VFQ-UI; estimate the contribution of
visual acuity in the BSE and WSE and other factors to utility;
and calculate WSE/BSE coefficient ratios; similar ratios have
previously been estimated at ~30% using ranibizumab
data.23,24 Herein we report the findings from these analyses.
METHODS
Study Data
Patient-level data from four studies evaluating IAI in DME
(VISTA-DME, VIVID-DME,22,25 VIVID-Japan [NCT01512966],
and VIVID-EAST [NCT01783886]) were available at the time
of analysis. The designs are summarized in Supplementary
Table S1. Only the visual acuity, NEI-VFQ-25, and EQ-5D
(VISTA-DME/VIVID-DME and VIVID-Japan only) data at base-
line, week 24, week 52, and week 100 (VISTA-DME/VIVID-
DME only) from these studies were included.
Derivation of Utility Data
Utility was measured using the generic EQ-5D and the vision-
specific VFQ-UI. The EQ-5D is a generic preference-based
measure with five single-item dimensions (mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression) each
with three levels.26 This study used a value set estimated by
preference elicited from the UK general population using time
trade-off.27 The VFQ-UI was calculated from the NEI-VFQ-25
questionnaire through application of the algorithm of Rentz et
al.14 One item from each of six NEI-VFQ-25 subscales (near
vision activities, distance vision activities, vision-specific social
functioning, role difficulties, dependency, and mental health)
was selected to develop a simplified eight vision-related health
state classification (from best to worst function) using clinical
input and Rasch analysis. These states were valued by 607
adults from the general population from four countries (UK,
Canada, Australia, and the United States) using a variant of time
tradeoff; these values represent direct valuation of VFQ states
rather than a mapping. Item response theory was used to
derive the severity score (theta) for each state, and regression
was used to map the severity score to a utility weight. In this
previous analysis the VFQ-UI was found to discriminate
significantly between BCVA levels. The algorithm of Rentz et
al.14 was applied to the NEI-VFQ-25 data in the four IAI studies
to derive VFQ-UI utilities. Only observed data were included in
the analyses, and missing data were not imputed.
Identification of Statistical Models
We used ordinary least squares (OLS) and random-effects panel
models. These models were chosen because they have been
applied in ophthalmology studies and described previous-
ly.3,6,19 A key assumption of OLS is that the error term is
independently distributed and not correlated across observa-
tions. However, one may expect that observations at different
time points from the same patient may be more correlated than
observations at different time points between different
patients. Therefore, a random-effects model, which relaxes
the assumption of independence between repeated observa-
tions from the same individuals, was also performed.
Generation of New Utility Data and Comparison of
Different Models
The relationship between vision and EQ-5D versus VFQ-UI
utility was enabled in the models using both the BSE (defined
independently at each time point as the eye with the highest
mean BCVA value of the two eyes) and the WSE (defined as that
with the lowest mean BCVA value of the two eyes) at any given
time point, and other factors, including patient characteristics.
The models were independent of treatment effects as data
from all treatment arms and time points were included.
The models are described algebraically as follows:
Uit ¼ b0þb1 lnVABSEit þ b2 lnVAWSEit þ b3ðlnVABSEit 3 lnVAWSEit Þ
þ b4Xit þ it
where Uit is utility (measured as VFQ-UI or EQ-5D utilities)
for patient i in time period t; VABSE(WSE) is vision health states
for the BSE (WSE); and X is a vector of covariates, including
patient characteristics (age, age squared [age2], sex [dummy
variable taking the value of 1 if the patient is male], and body
mass index [BMI]), medical history, and geographical region.
For the regression, concurrent clinical covariates were
adjusted using a reference category as follows: glycated
hemoglobin (HbA1c) (reference category: 8%), duration of
diabetes in years/quartiles (reference: second quartile), smok-
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ing status (reference: never smoked), hypertension (reference:
none), cardiovascular disease (reference: none), and diabetes
severity score from 0 to 5, which was based on the presence of
one or more of pseudophakia, diabetic neuropathy, diabetic
nephropathy, peripheral vascular disorder, and proteinuria.
The presence of none of these conditions was scored 0 and
presence of all five conditions was scored 5 (reference: score
0), and geographical region, with North America as the
reference category based on sample size.
For each regression model, a table of coefficients, standard
errors, P values, observation numbers, and goodness-of-fit
statistics are reported. These models enabled a comparison of
VFQ-UI with EQ-5D, and an estimation of the relative
contribution of visual acuity in the BSE and WSE to utility
was adjusted for the factors listed. There were three OLS
models that included a different set of covariates: model 1 (BSE
and WSE visual acuities); model 2 (BSE and WSE visual acuities,
age, age2, sex, and BMI); and model 3 (BSE and WSE visual
acuities, age, age2, sex, BMI, and concurrent clinical covariates
as described). Two random-effects models were reported: the
first included all covariates listed for OLS model 3 (best-fit
model), and the second was expanded to include an
interaction term for BSE and WSE. The WSE/BSE coefficient
ratios were calculated by dividing the WSE coefficient by the
BSE coefficient (OLS models). We calculated the expected
VFQ-UI or EQ-5D at different BSE and WSE visual acuity levels
or health states, using eight levels (>85, 85–76, 75–66, 65–56,
55–46, 45–36, 35–26, and <26 letters), thus generating a wide
range of new utility data.
Sensitivity analyses based on OLS model 3 were also
included. In these models, geographic region was replaced
by country (Australia, Austria, China, Czech Republic, Ger-
many, Denmark, Spain, France, Hong Kong, Hungary, Italy,
Japan, Korea, Poland, and Russia).
RESULTS
Study Data
Data from a total of 1320 patients with DME who were
enrolled in VISTA-DME, VIVID-DME, VIVID-EAST, and VIVID-
Japan were included. Most patients were enrolled from the
United States (35.3%), China (22.7%), and Japan (11.4%)
(Supplementary Table S1). Overall, the mean age was 61.7
years, 56.1% were male, and the mean BMI was 28.7 kg/m2; the
most common comorbidities were hypertension (70.9%) and
cardiovascular disease (23.9%) (Table 1). The mean baseline
visual acuity was 72.2 letters and 57.4 letters for the BSE and
WSE, respectively (Table 2). The mean baseline VFQ-UI and EQ-
5D scores were 0.78 and 0.81, respectively. The distribution of
VFQ-UI and EQ-5D utilities are shown in Supplementary Figure
S1; there was clustering around 1 for EQ-5D, but VFQ-UI was
more widely distributed.
Generation of New Utility Data and Comparison of
Different Models
There were 4991 VFQ-UI and 3736 EQ-5D observations
available for regression analysis (Table 3). In the OLS models,
the association between visual acuity (BSE and WSE) and VFQ-
UI was stronger than the association between visual acuity
(BSE and WSE) and EQ-5D–derived utilities, as shown by the
greater coefficients. These analyses also showed that the
regression coefficient for BSE visual acuity was consistently
greater than that observed with WSE visual acuity in all OLS
models (Table 4). In OLS model 3, for example, the regression
coefficients (SE) for BSE and WSE visual acuities and VFQ-UI
were 0.232 (0.014) and 0.075 (0.008) (both P < 0.001),
respectively. The regression coefficients for BSE and WSE visual
TABLE 1. Baseline Characteristics of DME Patients Enrolled in the IAI Studies?2
VISTA-DME VIVID-DME VIVID-EAST VIVID-Japan Total
N 466 404 377 73 1320
Age, years, mean (SD) 62.3 (9.8) 63.5 (8.3) 58.6 (10.2) 63.5 (9.5) 61.7 (9.7)
Male, % 54.3 61.9 50.4 64.4 56.1
BMI, kg/m2, mean (SD) 32.2 (7.3) 28.6 (5.2) 25.1 (3.7) 25.6 (5.5) 28.7 (6.4)
Pseudophakia, % 29.8 14.4 17.2 16.4 20.8
Diabetic neuropathy, % 12.4 13.9 7.4 11.0 11.4
Diabetic nephropathy, % 1.5 10.1 8.0 19.2 7.0
Peripheral vascular disorder, % 4.3 0.7 0.0 0.0 1.7
Proteinuria, % 7.1 1.2 1.9 0.0 3.4
Hypertension, % 84.3 73.5 52.3 67.1 70.9
Cardiovascular disease, % 31.8 23.5 13.8 28.8 23.9
Smoking status, %
Current 10.1 8.2 12.5 17.8 10.6
Former 32.6 36.2 13.0 34.3 28.2
Never 57.3 55.6 74.5 48.0 61.2
HbA1c, %
8% 64.2 64.4 70.8 82.2 67.1
>8% 34.8 34.9 28.9 16.4 32.1
Unknown 1.1 0.7 0.3 1.4 0.8
Diabetes duration, years, median 17 15 12 6 14
Diabetes severity score, n
0 259 278 262 45 844
1 164 96 100 23 383
2 36 23 15 4 78
3 7 7 0 1 15
4 0 0 0 0 0
5 0 0 0 0 0
IOVS j Month 2017 j Vol. 58 j No. 0 j 3
Allen Press, Inc.  1 September 2017  1:51 pm  Customer #IOVS-17-21945 Page 3
//titan/Production/i/iovs/live_jobs/iovs-58/iovs-58-11/iovs-58-11-14/layouts/iovs-58-11-14.3d RaNgE#?!1-8#?!
acuities and EQ-5D were 0.100 (0.027) (P < 0.001) and 0.042
(0.014) (P < 0.01), respectively. The regression coefficients for
BSE and WSE visual acuities were robust across all three VFQ-
UI models, even with an increasing number of covariates. The
coefficient of determination (R2) estimates were greater in the
three VFQ-UI models (range, 0.16–0.20) compared with the
three EQ-5D models (range, 0.01–0.13) even after including
comorbidities. The WSE/BSE coefficient ratios were more
similar across the VFQ-UI OLS models (32%) compared with
the EQ-5D models (41%–48%).
In the random-effects model (Table 5), there were also
stronger associations between BSE and WSE visual acuities
and VFQ-UI compared with the EQ-5D model. In the VFQ-UI
model, the regression coefficients (SE) were 0.213 (0.014) for
BSE visual acuity and 0.052 (0.007) for WSE visual acuity
(both P < 0.001). For EQ-5D, the regression coefficients (SE)
were 0.104 (0.029) (P < 0.001) for BSE visual acuity and
0.025 (0.014) for WSE visual acuity. Addition of the
interaction term for BSE and WSE was positive and statistically
significant but did not improve the model (Table 5). The R2s
suggest an approximate 20% association between visual
acuity and utility in the VFQ-UI models, compared with 13%
in the EQ-5D models, and a 62% correlation between actual
and predicted values. The correlation between the actual and
predicted values (q) was stronger with VFQ-UI than EQ-5D
(0.618 vs. 0.541). The actual (unadjusted) versus predicted
data plots also showed a better fit with VFQ-UI than EQ-5D-
derived utilities (Supplementary Figs. S2, S3). The actual and
predicted utilities in the eight-level visual acuity health states
for all analyses are shown in Supplementary Tables S2–S4. The
results for both sets of utility instruments did not differ in the
sensitivity analyses, which replaced region by country for
either the OLS or random-effects models (Supplementary
Table S5).
DISCUSSION
This paper explores the relationship between visual acuity and
health-related quality of life in DME using data from four IAI
studies22 (NCT01512966 and NCT01783886). The algorithm of
Rentz et al.14 was successfully applied, resulting in the
generation of usable VFQ-UI utilities from actual study data
valued by general population samples. Utility was modeled as a
function of BSE and WSE vision health states, and clinical
covariates (age, age2, sex, BMI, smoking status, HbA1c,
diabetes severity, comorbidities, and geographic region) were
included in OLS and random-effects regression analysis of the
best-fit model. The study was also feasible, in part, due to the
volume of data available and the wide range of visual acuities.
This is not the case for other conditions in which IAI has been
studied, such as neovascular AMD edema secondary to central
or branch retinal vein occlusion, or myopic choroidal
neovascularization. This is also the first study to compare
VFQ-UI with EQ-5D in DME; it has previously been compared
with EQ-5D in 224 patients with uveitis treated with
dexamethasone implants (0.35 or 0.7 mg) or sham for 26
weeks.28 In this study, patients completed the NEI VFQ-25 at
screening and at weeks 8, 16, and 26/exit, and the EQ-5D and
SF-36 Health Survey (SF-36) at screening only. The VFQ-UI
demonstrated good internal consistency with the NEI VFQ-25,
independent of treatment effects, The VFQ-UI and EQ-5D were
moderately correlated at screening; however, only 21%–24% of
variance was shared between the vision-related and generic
preference measures. These authors also concluded that
generic measures may not be sensitive for assessing impair-
ments in vision-related functioning.
Our study showed that both OLS and random-effects
models were suitable for examining patient utility in DME,
even when an increasing number of covariates were included.
However, the consistency of the R2 value and WSE/BSE
TABLE 2. Visual Acuities and Utility Scores for DME Patients Enrolled in the IAI Studies
VISTA-DME VIVID-DME VIVID-EAST VIVID-Japan Total
N 466 404 377 73 1320
BSE, mean visual acuity (n)
Baseline 71.8 (466) 72.7 (403) 67.5 (377) 71.5 (73) 72.2 (942)
Week 24 76.0 (431) 76.2 (380) 71.2 (363) 73.3 (71) 75.9 (882)
Week 52 77.8 (360) 77.7 (311) 72.9 (355) 74.5 (66) 77.5 (737)
Week 76 78.5 (329) 78.2 (285) – – 78.3 (614)
Week 100 76.7 (298) 78.9 (263) – – 79.3 (561)
WSE, mean visual acuity (n)
Baseline 56.9 (466) 58.5 (403) 54.3 (377) 54.3 (73) 57.4 (942)
Week 24 63.3 (431) 63.2 (380) 58.6 (363) 60.3 (71) 63.0 (882)
Week 52 66.0 (360) 66.0 (311) 62.8 (355) 61.2 (66) 65.5 (737)
Week 76 66.9 (329) 66.8 (285) – – 66.9 (614)
Week 100 68.8 (298) 66.8 (263) – – 67.8 (561)
VFQ-UI score, mean (n)
Baseline 0.78 (465) 0.81 (404) 0.76 (376) 0.79 (73) 0.78 (1318)
Week 24 0.81 (431) 0.82 (381) 0.78 (360) 0.83 (71) 0.81 (1243)
Week 52 0.83 (360) 0.84 (357) 0.79 (353) 0.82 (66) 0.82 (1136)
Week 76 0.84 (329) 0.84 (342) – – 0.84 (671)
Week 100 0.85 (297) 0.85 (326) – – 0.85 (623)
EQ-5D, mean (n)
Baseline 0.78 (466) 0.83 (403) – 0.89 (73) 0.81 (942)
Week 24 0.78 (431) 0.83 (380) – 0.88 (71) 0.81 (882)
Week 52 0.79 (360) 0.85 (311) – 0.92 (66) 0.83 (737)
Week 76 0.81 (329) 0.85 (285) – – 0.83 (614)
Week 100 0.81 (298) 0.86 (263) – – 0.83 (561)
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TABLE 3. Number of VFQ-UI and EQ-5D Observations by Eight-Level Visual Acuity Health States?3
VFQ-UI
WSE visual acuity (letters)
BSE visual acuity (letters)
>85 85–76 75–66 65–56 55–46 45–36 35–26 <26 Total
>85 100 100
85–76 289 511 800
75–66 186 817 538 1541
65–56 64 429 493 237 1223
55–46 20 167 220 200 94 701
45–36 10 48 90 92 58 34 332
35–26 2 21 46 39 32 26 19 185
<26 2 13 26 18 23 13 9 5 109
Total 673 2006 1413 586 207 73 28 5 4991
EQ-5D
>85 79 79
85–76 262 389 651
75–66 171 667 352 1190
65–56 60 333 369 145 907
55–46 17 134 167 142 42 502
45–36 9 34 63 60 36 12 214
35–26 2 15 30 24 24 9 10 114
<26 2 11 22 13 18 8 4 1 79
Total 602 1583 1003 384 120 29 14 1 3736
TABLE 4. Association Between VFQ-UI– and EQ-5D–Derived Utilities and Visual Acuity Using OLS Models Adjusted for Different Baseline
Characteristics
VFQ-UI EQ-5D
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3
RC SE RC SE RC SE RC SE RC SE RC SE
Observations 4967 4955 4571 3716 3705 3654
Intercept –0.465‡ 0.045 –0.407‡ 0.059 –0.397‡ 0.064 0.265† 0.101 0.471‡ 0.131 0.410† 0.127
Log (BSE visual acuity) 0.228‡ 0.013 0.227‡ 0.013 0.232‡ 0.014 0.093† 0.029 0.088† 0.028 0.100‡ 0.027
Log (WSE visual acuity) 0.073‡ 0.008 0.072‡ 0.007 0.075‡ 0.008 0.038* 0.015 0.042† 0.014 0.042† 0.014
Age –0.003* 0.001 –0.004† 0.001 0.000 0.003 –0.003 0.003
Age2 0.000† 0.000 0.000‡ 0.000 0.000 0.000 0.000 0.000
Male 0.019‡ 0.004 0.017‡ 0.004 0.035‡ 0.007 0.055‡ 0.007
BMI 0.000 0.000 0.000 0.000 –0.006‡ 0.001 –0.004‡ 0.001
HbA1c >8% –0.008* 0.004 –0.005 0.007
Diabetes duration (quartile 1) 0.006 0.005 0.025* 0.010
Diabetes duration (quartile 3) –0.018† 0.005 –0.007 0.010
Diabetes duration (quartile 4) –0.013* 0.005 –0.036‡ 0.010
Diabetes severity 1 –0.028‡ 0.004 –0.062‡ 0.008
Diabetes severity 2 –0.029‡ 0.008 –0.041† 0.014
Diabetes severity 3 –0.046† 0.016 –0.054* 0.026
Hypertension –0.011* 0.005 –0.029† 0.009
Cardiovascular disease –0.027‡ 0.005 –0.074‡ 0.008
Current smoker -0.002 0.007 –0.054‡ 0.012
Former smoker 0.000 0.004 –0.016* 0.008
Europe and Australia 0.003 0.004 –0.007 0.008
Japan –0.006 0.007 0.068‡ 0.011
Other Asia-Pacific region –0.037‡ 0.006
Adjusted R2 0.16 0.17 0.20 0.01 0.06 0.13
WSE/BSE ratio 32% 32% 32% 41% 48% 42%
WSE/BSE ratio refers to the ratio of coefficients. Log, logarithm; RC, regression coefficient.
* P < 0.05.
† P < 0.01.
‡ P < 0.001. (P value > t-statistic).
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coefficient ratios across the OLS models suggests that this may
be a more robust approach. Across all models, the association
between visual acuity (BSE and WSE) and VFQ-UI was
stronger in terms of coefficient size and statistical significance
than the association between visual acuity (BSE and WSE) and
EQ-5D–derived utilities. These findings indicate that VFQ-UI–
derived utilities are a suitable alternative to EQ-5D in DME
evaluations.
The stronger association between visual functioning and
utilities derived from an ophthalmologic-specific measure,
such as the NEI-VFQ-25, is consistent with studies in other
retinal conditions.3,29 In their analysis, Kay et al.29 mapped
NEI-VFQ-25 to EQ-5D using data from DME patients enrolled in
the RESTORE study; this approach resulted in low predictive
power, possibly due to the insensitivity of the EQ-5D to
discriminate vision-related activities. In the current analyses,
we applied the algorithm of Rentz et al. to develop the VFQ-UI,
which represents direct valuation of VFQ states rather than
mapping to avoid this limitation.
The current VFQ-UI calculations also provide new utilities
data for DME and will be beneficial in future health technology
assessments of DME treatments. In a previous assessment of
IAI in DME that was submitted to NICE (NICE TA346), the
bilateral BCVA utilities, which were based on the work of
Czoski-Murray et al.,30 were estimated for the WSE by assuming
that the change in utility in the WSE was 30% lower than that
observed in the BSE based on the difference in visual acuity
between them. Although NICE considered such estimates
acceptable for decision-making, they added that it was not an
ideal approach. The utility estimates were based on AMD-
simulated vision states and subsequent EQ-5D assessments in a
limited sample of healthy volunteers from a UK population and
were not based on treatment outcomes in DME patients.
Although the current WSE/BSE coefficient ratios were also
approximately 30% in the VFQ-UI OLS models, this estimate
was based on actual, albeit log-transformed, data in DME
patients. There was, however, slightly wider variation with the
EQ-5D models.
Previous coefficients for ranibizumab have also been
estimated at 30%; these are largely based on RESTORE, ?4in
which vision changes following treatment in the WSE had
~30% of the heath-related quality of life impact for the same
vision changes following treatment in the BSE.23,24 It must be
noted that these are estimates and relate to health-related
quality of life rather than health utility. We have developed
accurate models to determine the coefficients for IAI using
actual data and we cannot exclude the possibility that this
similarity is coincidental.
The outcomes from the statistical models also showed that
the regression coefficient for BSE visual acuity was consistently
greater than that observed for WSE visual acuity in all models,
which confirms that that the WSE is important, although less
so compared with the BSE. A number of other studies have also
reported a correlation between baseline visual acuity and NEI-
VFQ-25.31–33 This indicates that the distinction between BSE
and WSE is beneficial for assessing treatment outcomes,
particularly when considering the definition and also the
impact of only including one study eye in long-term treatment
TABLE 5. Association Between VFQ-UI– or EQ-5D–Derived Utilities and Visual Acuity Using a Random-Effects Model Adjusted for Different Baseline
Characteristics and With Interactive Term for BSE and WSE Visual Acuities
Model Without Interaction Model With Interaction
VFQ-UI EQ-5D VFQ-UI EQ-5D
RC SE RC SE RC SE RC SE
Observations 4571 3654 4571 3654
Intercept –0.344‡ 0.064 0.416† 0.129 0.936* 0.387 1.105 0.761
Log (BSE visual acuity) 0.213‡ 0.014 0.104‡ 0.029 –0.088 0.091 –0.057 0.178
Log (WSE visual acuity) 0.052‡ 0.007 0.025 0.014 –0.289† 0.102 –0.159 0.200
Log (BSE visual acuity) * Log (WSE visual acuity) – – – – 0.080† 0.024 0.043 0.046
Age 0.001* 0.000 0.001 0.001 0.001† 0.000 0.001 0.001
Male –0.016* 0.007 –0.050‡ 0.012 –0.015* 0.007 –0.050‡ 0.012
BMI 0.001 0.001 –0.004‡ 0.001 0.001 0.001 –0.004‡ 0.001
HbA1c >8% –0.008 0.007 0.002 0.012 –0.009 0.007 0.002 0.012
Diabetes duration (quartile 1) 0.003 0.009 0.020 0.017 0.004 0.009 0.020 0.017
Diabetes duration (quartile 3) –0.014 0.009 –0.004 0.016 –0.013 0.009 –0.004 0.016
Diabetes duration (quartile 4) –0.012 0.009 –0.042† 0.016 –0.013 0.009 –0.042† 0.016
Diabetes severity 1 –0.029‡ 0.007 –0.062‡ 0.013 –0.028‡ 0.007 –0.061‡ 0.013
Diabetes severity 2 –0.020 0.014 -0.036 0.023 –0.019 0.014 –0.035 0.023
Diabetes severity 3 –0.055* 0.028 –0.048 0.044 –0.054 0.028 –0.048 0.044
Hypertension –0.011 0.008 –0.034* 0.014 –0.010 0.008 –0.033* 0.014
Cardiovascular disease –0.025† 0.008 –0.074‡ 0.013 –0.025† 0.008 –0.074‡ 0.013
Current smoker 0.002 0.011 –0.042* 0.020 0.003 0.011 –0.042* 0.020
Former smoker 0.002 0.008 –0.014 0.013 0.002 0.008 –0.014 0.013
Europe and Australia 0.007 0.008 –0.005 0.013 0.007 0.008 –0.005 0.013
Japan –0.003 0.011 0.063† 0.018 –0.001 0.011 0.064‡ 0.018
Other Asia-Pacific region –0.037‡ 0.010 –0.035† 0.010
Adjusted overall R2 0.20 0.14 0.20 0.14
WSE/BSE ratio 24% 24% NA NA
Correlation between actual and predicted 0.618 0.541 0.617 0.541
WSE/BSE ratio refers to the ratio of coefficients. NA, not applicable due to interactive term.
* P < 0.05.
† P < 0.01.
‡ P < 0.001 (P value > z-statistic).
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assessments in clinical studies. In a systematic review,
Hirneiss21 also found that visual functioning in the WSE had
a greater effect on quality of life than previously assumed,
although research was hampered by lack of a consistent
definition of BSE and WSE. In contrast to previously used
definitions,23,24 the current findings are based on simplified
definitions of WSE and BSE for use with either measure (EQ-5D
and VFQ-UI) that produce easy to use coefficients across
several models. The ongoing AQUA and VIOLET studies?5
(clinicaltrials.gov), which are further evaluating IAI regimens
in DME patients, will include NEI-VFQ-25 assessments in
addition to visual acuity outcomes in the BSE and WSE to
enable further estimates of the relationship between them.
These studies are expected to be completed in 2017 and 2019,
respectively. A systematic review and meta-analysis of the
available utility data in patients with diabetic retinopathy is also
under way.34 It is hoped that this will provide a protocol for
use in selecting data for decision analytic models and health
technology assessments.
Although the analyses did adjust for baseline characteris-
tics, such as age and sex, there are a number of limitations
inherent with cross-sectional regression models. The use of
pooled data from four different studies and diverse popula-
tions may introduce heterogeneity. It must also be noted that
in the VISTA-DME and VIVID-DME studies,?6 improvements in
the NEI-VFQ-25 from baseline were observed over time, but
differences between the treatments (IAI 2 mg every 4 weeks
[2q4] and every 8 weeks [2q8] versus laser) were limited;
however, the difference between treatments (IAI 2q8 versus
laser) in the VIVID-EAST study was significant. All studies
prespecified that the WSE was the study eye and anti-VEGF
treatment was allowed in the non–study eye, but the impact
of these inclusion criteria on NEI-VFQ-25 is not fully
understood.
Caution should be applied when directly comparing VFQ-UI
and EQ-5D measures of vision-specific and generic health
utility. Nevertheless, the lack of association between the two
health utility measures appears fairly marked (Supplementary
Fig. S4). This may be anticipated from these instruments given
that the EQ-5D is a generic measure that has been applied to a
DME population that also has a range of comorbid illnesses,
which would contribute to utility outcomes, or it could be
from sampling variation. However, this lack of association also
suggests that EQ-5D underestimates the impact of visual acuity
on utility.
In summary, this paper explores the relationship between
BSE and WSE visual acuities and both generic and condition-
specific, preference-based health measures (EQ-5D and VFQ-
UI) using regression analyses of data from four IAI studies in
DME. The analyses show that VFQ-UI was more sensitive than
EQ-5D for measuring the impact of visual acuity in the BSE and
WSE on utilities, and models were more robust to the addition
of other explanatory factors. Not surprisingly, visual acuity in
the BSE was shown to be a major contributor to health-related
quality of life, but the findings confirm that the WSE
contribution was ~30%, which is similar to the estimate used
in previous publications. From a practical perspective, these
analyses provide new and specific utilities data, which may
prove valuable in future health technology assessments in
DME. These results highlight the importance of both the BSE
and WSE on quality of life and the importance and usability of
NEI-VFQ-25 data. Use of the utility data generated in these
analyses for health technology assessments in other retinal
conditions or treatments is limited because the analyses were
based on health-related quality of life responses in DME
patients treated with IAI and/or laser, but these data may be
useful where alternatives are sparse.
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